Fed Circuit reinstates $235m verdict against Teva

In a victory for GlaxoSmithKline (GSK), the US Court of Appeals for the Federal Circuit has revived a 2017 jury verdict ordering Teva to pay $235 million over the drug Coreg (Carvedilol).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Skinny-label ruling will ‘decimate’ Hatch-Waxman, Fed Circuit told

5 January 2021 One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation.

Americas

Teva urges Fed Circuit to save skinny label law from ‘nullification’

3 December 2020 Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.

Americas

Celgene, Teva execs grilled over price hikes

1 October 2020 A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Fed Circuit reinstates $235m verdict against Teva

More on this story

Editor's picks

Editor's picks

More features